(Press-News.org) About The Study: This randomized clinical trial demonstrates the potential clinical utility of plozasiran, an investigational APOC3-targeted small interfering–RNA drug, to reduce triglyceride level in patients with severe hypertriglyceridemia. Additional studies will be required to determine whether plozasiran favorably modulates the risk of severe hypertriglyceridemia-associated complications.
Authors: Daniel Gaudet, M.D., Ph.D., of the Université de Montréal, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.0959)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with presentation at the American College of Cardiology’s Annual Scientific Session.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.0959?guestAccessKey=0ae3b504-dfb6-4e89-8883-c74f4f743edf&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040724
END
Plozasiran (ARO-APOC3) for severe hypertriglyceridemia
JAMA Cardiology
2024-04-07
ELSE PRESS RELEASES FROM THIS DATE:
Experimental drug could further reduce lipids in the blood in high-risk patients
2024-04-07
Hypertriglyceridemia, or high levels of lipids (fats) in the blood, increases the risk of heart attack, stroke and acute pancreatitis. Currently available medications, including statins, ezetimibe, fibrates and prescription omega 3 fatty acids, typically lower triglyceride levels by anywhere from below 10% to up to 40%. These therapies help, but they are not enough to prevent cardiovascular events in everyone.
An experimental treatment could further lower triglycerides in the blood, according to a placebo-controlled ...
New evidence links passive smoking with dangerous heart rhythm disorder
2024-04-07
Berlin, Germany – 7 April 2024: Exposure to secondhand smoke – even at small amounts – is linked with greater risk of a serious heart rhythm disorder, according to research presented at EHRA 2024, a scientific congress of the European Society of Cardiology (ESC).1 The likelihood of atrial fibrillation increased as the duration of passive smoking lengthened.
“The dangers of secondhand smoke were significant regardless of whether individuals were at home, outdoors, or at work, indicating that exposure universally elevates the risk of atrial ...
Oral vaccine for UTI is potential alternative to antibiotics, finds 9-year study
2024-04-07
Recurrent Urinary Tract Infections (UTIs) can be prevented for up to nine years in more than half of people given an oral spray-based vaccine and is a potential alternative to antibiotic treatments, finds research.
Initial results from the first long-term follow-up study of the safety and effectiveness of the MV140 vaccine for recurrent UTIs are presented this weekend at the European Association of Urology (EAU) Congress in Paris.
They show that in both men and women with recurrent UTIs, 54% of study participants remained UTI-free for nine years after the vaccine, with no notable side effects reported. Full results of the study are expected to be published ...
Antibiotic prophylaxis and infective endocarditis incidence following invasive dental procedures
2024-04-06
About The Study: This systematic review and meta-analysis including data on 1.1 million cases of infective endocarditis found that antibiotic prophylaxis was associated with a reduced risk of infective endocarditis following invasive dental procedures in individuals at high risk but not in those at moderate or low/unknown risk. Currently, there is insufficient data to support any benefit of antibiotic prophylaxis in individuals at moderate risk.
Authors: Federica Turati, Ph.D., of the ...
A multimodal video-based AI biomarker for aortic stenosis development and progression
2024-04-06
About The Study: In this cohort study of patients without severe aortic stenosis undergoing echocardiography or cardiac magnetic resonance imaging, a new artificial intelligence (AI)-based video biomarker was independently associated with aortic stenosis development and progression, enabling opportunistic risk stratification across cardiovascular imaging modalities as well as potential application on handheld devices.
Authors: Rohan Khera, M.D., M.S., of the Yale School of Medicine in New Haven, Connecticut, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.0595)
Editor’s ...
Inter-atrial shunts may benefit some heart failure patients while harming others
2024-04-06
Inter-atrial shunts—investigational devices that create a small pathway for blood to pass from the left to the right side of the heart in order to improve heart failure symptoms and outcomes—may be beneficial to heart failure patients with reduced left ventricular ejection fraction (LVEF) but harmful or even deadly for heart failure patients with preserved LVEF, a new Mount Sinai-led study shows.
The findings of the RELIEVE-HF trial were announced during the opening late-breaking trial session at the American College of Cardiology Scientific Sessions on Saturday, April 6. This is the first study ...
Prostate cancer screening with PSA, Kallikrein Panel, and MRI
2024-04-06
About The Study: In this preliminary descriptive report from an ongoing randomized clinical trial, one additional high-grade cancer per 196 men and one low-grade cancer per 909 men were detected among those randomized to be invited to undergo a single prostate cancer screening intervention compared with those not invited to undergo screening. These preliminary findings from a single round of screening should be interpreted cautiously, pending results of the study’s primary mortality outcome.
Authors: Anssi ...
PSA screening and 15-year prostate cancer mortality
2024-04-06
About The Study: A single invitation for prostate-specific antigen (PSA) screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years in this secondary analysis of a randomized clinical trial. However, the absolute reduction in deaths was small.
Authors: Richard M. Martin, B.M., B.S., Ph.D., of the University of Bristol in Bristol, United Kingdom, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.4011)
Editor’s ...
Screening with a PSA test has a small impact on prostate cancer deaths but leads to overdiagnosis
2024-04-06
The largest study to date investigating a single invitation to a PSA blood test* to screen for prostate cancer has found it had a small impact on reducing deaths, but also led to overdiagnosis and missed early detection of some aggressive cancers.
The CAP trial, published in the Journal of the American Medical Association (JAMA) and carried out by researchers from the universities of Bristol, Oxford and Cambridge, involved over 400,000 men aged 50-69. Just under half received a single invitation for a PSA test as part of the trial.
After following up for 15 years, there was a small difference in the number of men who died from prostate cancer between the ...
Five-year interval is safe for prostate cancer screening, research shows
2024-04-06
A simple blood test every five years is sufficient to screen low risk men for prostate cancer, new research has shown.
The PSA blood test checks the level of prostate-specific antigen, a marker for prostate cancer. In Europe, only Lithuania routinely screens men for prostate cancer based on their PSA levels, as the test has historically been seen as insufficiently reliable.
The German study, presented at the European Association of Urology (EAU) Congress in Paris today [April 6, 2024], involved over 12,500 men aged between 45-50 taking part in the ongoing ...
LAST 30 PRESS RELEASES:
Key to the high aggressiveness of pancreatic cancer identified
How proactive salmon conservation in the North Pacific can deliver global benefits
Blocking chemokine receptor increases effectiveness of glucocorticoids in multiple myeloma treatment
Amount of sunlight reaching Earth’s surface varies over decades, researchers report
Heart valve abnormality is associated with malignant arrhythmias
Explainable AI for ship navigation raises trust, decreases human error
Study reveals erasing inequality could prevent hundreds of adverse births annually in major UK city
No “uncanny valley” effect in science-telling AI avatars
New UNCG research shows southern shrews shrink in winter
Children exposed to brain-harming chemicals while sleeping
Emotions and levels of threat affect communities’ resilience during extreme events
New CONSORT reporting guidelines published today in five medical journals
Experts stress importance of vaccination amidst measles outbreaks
Enabling stroke victims to 'speak': $19 million toward brain implants to be built at U-M
Study captures sharp uptake in use of new weight loss and glucose-lowering medications
Van Andel Institute to recognize Dr. J. Timothy Greenamyre with 2025 Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research
One firearm injury was treated every 30 minutes in emergency departments in a study of 10 jurisdictions
The gut health benefits of sauerkraut
Children’s Hospital of Philadelphia researchers chart natural history of patients with SCN8A-related disorders
Archaeologists measured and compared the size of 50,000 ancient houses to learn about the history of inequality -- they found that it’s not inevitable
Peptide imitation is the sincerest form of plant flattery
Archaeologists discover historical link between inequality and sustainability
Researchers develop an LSD analogue with potential for treating schizophrenia
How does our brain regulate generosity?
New study reveals wealth inequality’s deep roots in human prehistory
New archaeological database reveals links between housing and inequality in ancient world
New, non-toxic synthesis method for “miracle material” MXene
Cutting-edge optical genome mapping technology shows promise for diagnosis, prognosis, and therapeutic options of multiple myeloma
Study looks at impact of COVID-19 pandemic on rates of congenital heart disease procedures among children
UH researcher unveils new model to evaluate impact of extreme events and natural hazards
[Press-News.org] Plozasiran (ARO-APOC3) for severe hypertriglyceridemiaJAMA Cardiology